Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Haleon CH SARL

Home Clinical Trial Sponsors and OrganizationsHaleon CH SARL

Haleon CH SARL

Route de l'Etraz, Prangins, Vaud, Switzerland

Also known as:

GSK Consumer Healthcare

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

0 active

Approvals

12

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

66.7%

Phase 4

1

33.3%

Trial Status Distribution

Completed

2

66.7%

Recruiting

1

33.3%

Clinical Trials

Trials sponsored by this organization (3)

A Randomized, Open label, Single Center, Single Oral Dose, Four Treatment, Four Period, Four Sequence, Crossover Bioavailability Study of Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) vs. Panadol Advance Tablets 2X (paracetamol 500 mg), Naprosyn Tablets 1X (naproxen 250 mg), administered individually in fasted conditions and Haleon Immediate Release Tablets 2X (paracetamol/naproxen 500 mg/125 mg) in fed conditions in Healthy Adult Participants

Sep 202652 participants

Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants

May 202612 participants

A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to assess Bioequivalence with Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions

54 participants

Approvals

Approvals by Agency

SFDA

Saudi Food and Drug Authority

8

Approvals

NPRA

National Pharmaceutical Regulatory Agency

4

Approvals

Recent Approvals

LAMISIL CREAM 1%

Lamisil 1% DermGel

Voltaren 12 Hours Emulgel 2% Gel

Voltaren Emulgel 1%

VOLTAREN EMULGEL 1%

VOLTAREN EMULGEL 1%

FENISTIL DROPS 0.1G-100ML

OTRIVIN NASAL DROPS 0.1%

OTRIVIN NASAL DROPS 0.05%

OTRIVIN MENTHOL 0.1% NASAL SPRAY

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals12
News

Back to Organizations